Welcome to our dedicated page for Bluejay Diagnostics news (Ticker: BJDX), a resource for investors and traders seeking the latest updates and insights on Bluejay Diagnostics stock.
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) is a medical diagnostics company developing the Symphony near-patient testing platform and the Symphony IL-6 Test for sepsis triage and monitoring. The BJDX news feed features company announcements that trace Bluejay’s progress across clinical development, manufacturing partnerships, regulatory planning, and financing activities related to its critical-care diagnostics strategy.
Readers can follow updates on the SYMON Clinical Study Program, including the SYMON-I pilot study and the pivotal SYMON-II trial, which are designed to evaluate IL-6 as a prognostic biomarker for mortality and other endpoints in sepsis and ICU patients. News items describe how Bluejay plans to use data from these studies to support a future 510(k) submission for the Symphony IL-6 test and to advance its goal of providing rapid, near-patient diagnostics for critical care.
The BJDX news stream also covers manufacturing and supply-chain developments, such as amendments to the company’s Master Service and Master Supply Agreements with SanyoSeiko Co., Ltd. and updates on its amended license and supply arrangements with Toray Industries, Inc. These releases detail SanyoSeiko’s expanded role in analyzer and cartridge manufacturing, as well as Bluejay’s efforts to secure alternative cartridge manufacturing capabilities and regulatory-grade supply chain readiness.
In addition, Bluejay’s news includes capital markets and corporate updates, including private placements, warrant inducement transactions, and a reverse stock split, along with commentary on how the company intends to use proceeds to fund clinical studies, regulatory activities, and working capital. Investors and observers can use this page to review historical press releases, clinical milestones, manufacturing agreements, and financing disclosures that shape the company’s development of the Symphony IL-6 test and its broader critical-care diagnostics platform.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) reported its financial results for 2022, highlighting key developments in its Symphony platform, aimed at improving patient outcomes in critical care. The company received positive FDA feedback on expanding its clinical study, pushing the anticipated de novo submission to the first half of 2024. As of December 31, 2022, cash and equivalents decreased to $10.1 million from $19.0 million in 2021. Research and development expenses surged by 262% to $3.0 million, while general and administrative costs increased by 166%. The net loss for the year was $9.3 million, or $0.46 per share, compared to $3.5 million, or $0.41 per share in 2021.